1. Bellasio E., Parravicini F. e Testa E. (1969): Sintesi di 3-idrazinopiridazine con sostituenti basici in posizione 6 dotate di attivitá ipotensiva. II Farmaco Ed. Sci.,24, 919–929.
2. Baldoli E., Sardi A., Dezulian V., Capellini M. and Bianchi G. (1973): On the pharmacology of 3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino] -pyridazine-dihychloride (L 6150). Arzneimittel-Forsch. Drug. Res.,23, 1591–1595.
3. De Ponti C. and Bardi U. (1976): A comparative study of the haemodynamic effects of single intravenous doses of 3 -h y d r a z i no-6-[N,N-bis-(2-hydroxyethyl)amino] -pyridazine-dihydrochloride and hydralazine. Arzneimittel-Forsch. Drug. Res.,26, 2089–2092.
4. Pasotti C, Nicrosini F., Marchetti M., Manzini A. and Nicolis F.B. (1976): Bioassay of the vasodepressor and cardiostimulatory effects of hydralazine and pyridazine derivative (DL 150) in hypertensive patients. II Farmaco Ed. Pr.,31, 453–462.
5. Maseri A., Pesola A., L’Abbate A., Contini C. and Magini G. (1976): Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. J. Int. Med. Res.,4, 402–409.